Efficacy and Safety Study of Vandetanib (ZD 6474) in Combination With Bicalutamide Versus Bicalutamide Alone in Patients With Chemotherapy Naive Hormone Refractory Prostate Cancer.

• Status: Completed
• Trial end date: 2012-11-01

Summary

Purpose To define the efficacy, tolerability and safety of Vandetanib in combination with bicalutamide in patients with chemotherapy naive hormone refractory prostate cancer

Hypothesis There will be a PSA response when Vandetanib is given in combination with Bicalutamide in Chemotherapy Naive Hormone refractory prostate cancer patients.

• Phase: Phase 2

Details

• Lead Sponsor: British Columbia Cancer Agency
• Collaborator: AstraZeneca
• Treatments: Bicalutamide; Hormones